Early Parkinson Disease
Key Points
Key Points
- The treatment options for the alleviation of motor symptoms in the early stages of Parkinson disease (PD) are based on the enhancement of dopaminergic tone with levodopa, monoamine oxidase inhibitors, dopamine agonists (DAs), or a combination thereof.
- The choice of initial treatment is influenced by the potential for neuropsychiatric adverse effects associated with DAs and dyskinesia and motor fluctuations associated with levodopa.
Treatment
...reatment
...odopa vs. DAs vs. MAO-B inhi...
...cians should counsel patients with early PD on...
...patients with early PD who seek trea...
...prescribe DAs as the initial dopamin...
...nicians should not prescribe DAs to patien...
...cribing levodopa...
...d initially prescribe immediate-release levodopa...
...s with early PD, clinicians should prescribe...
...nicians should routinely monitor patients...
...nicians should counsel patients takin...
...cians should counsel patients that in later dis...
...escribing DAs...
...ould inform the patient and caregiv...
...ians should screen patients for cognitive impairm...
...ould screen patients for the presence of a...
...ould involve caregivers in assessm...
...icians may screen patients for the presence o...
...should integrate patient preferences concernin...
Clinicians should prescribe the lowest...
...ing and Discontinuing DAs...
...icians should recommend tapering or discontin...
...As must be discontinued due to adverse...
...ng MAO-B inhibitors...
...should counsel patients with early PD on the great...
...ans may prescribe MAO-B inhibitors as the i...
...ations for Parkinson DiseaseHaving trouble v...